Search clinical trials for: MGL-3196

Total 11942 results

Madrigal Pharmaceuticals, Inc.
Celerion

Completed

Bioavailability Study of MGL-3196 Tablets Compared to Capsules

Healthy

United States
Madrigal Pharmaceuticals, Inc.
Worldwide Clinical Trials

Completed

Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196

Healthy

United States
Madrigal Pharmaceuticals, Inc.

Completed

Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects

Hepatic Impairment | NASH - Nonalcoholic Steatohepatitis | Cirrhosis, Liver

United States
Madrigal Pharmaceuticals, Inc.

Completed

Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

Heterozygous Familial Hypercholesterolemia

Denmark
Madrigal Pharmaceuticals, Inc.

Unknown

Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)

Non-alcoholic Steatohepatitis

United States
Madrigal Pharmaceuticals, Inc.

Recruiting

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

Non-Alcoholic Fatty Liver Disease

United States, Puerto Rico
Madrigal Pharmaceuticals, Inc.

Recruiting

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

Cirrhosis, Liver | NASH

United States, Puerto Rico
Madrigal Pharmaceuticals, Inc.

Completed

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients (MAESTRO-NAFLD1)

Non-Alcoholic Fatty Liver Disease

United States, Puerto Rico
Madrigal Pharmaceuticals, Inc.

Active, not recruiting

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis (MAESTRO-NASH)

NASH - Nonalcoholic Steatohepatitis

United States, Spain, Australia, United Kingdom, Canada, Israel, Belgium, Italy, France, Puerto Rico, Switzerland, Germany, Austria, Poland, Mexico, Hungary
Madrigal Pharmaceuticals, Inc.

Completed

Drug Interaction Study of MGL-3196 With Pioglitazone

Healthy

United States
Madrigal Pharmaceuticals, Inc.

Completed

Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects

Drug Safety

United States
Madrigal Pharmaceuticals, Inc.

Completed

Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects

Drug Safety

United States
Madrigal Pharmaceuticals, Inc.
Celerion

Completed

Drug Interaction Study of MGL-3196 With Atorvastatin

Healthy

United States
Madrigal Pharmaceuticals, Inc.
Celerion

Completed

Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin

Healthy

United States
Tau Pnu Medical Co., Ltd.

Completed

The Effect of "Cerclage Pacing" for the Heart Failure Patients Who Need Cardiac Resynchronization Therapy (CRT) (Cerclage-CRT)

Heart Failure | LBBB Complete

Korea, Republic of
Acerta Pharma BV
AstraZeneca

Active, not recruiting

Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies

Multiple Myeloma | Non-Hodgkins Lymphoma | B-All

United States
Laboratoires URGO

Completed

Assessment of Efficacy & Tolerance of Urgo 310 3166 Dressing in Local Venous or Mixed Leg Ulcers (CASSIOPEE)

Ulcers, Leg

France
Inovio Pharmaceuticals
University of Pennsylvania

Completed

Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies

Aerodigestive Precancerous Lesions and Malignancies

United States
Madrigal Pharmaceuticals, Inc.

Completed

Drug Interaction Study of MGL-3196 With Clopidogrel

Healthy

United States
AbbVie

Recruiting

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Chronic Lymphocytic Leukemia

United States, Australia, Canada, Israel
Acerta Pharma BV

Active, not recruiting

Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Syneos Health
SynerK Pharmatech (Suzhou) Limited

Recruiting

Dose Escalation of SNK-396 in Participants With Elevated Low-Density Lipoprotein Cholesterol

Elevated Low-Density Lipoprotein Cholesterol

Australia
Herbert Lyerly

Terminated

A Study of HS-196, an HSP90 Inhibitor-linked NIR Probe for Solid Malignancies

Solid Tumor

United States
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of MCI-196 in Patients With Type 2 Diabetes

Type 2 Diabetes
Betta Pharmaceuticals Co., Ltd.

Completed

Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK

Solid Tumor | Non-Small Cell Lung Cancer Metastatic

China
Acerta Pharma BV

Completed

A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants

Healthy Volunteers

United States
Acerta Pharma BV
Merck Sharp & Dohme LLC

Completed

ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer (KEYNOTE144)

Metastatic Pancreatic Cancer

United States
Chong Kun Dang Pharmaceutical

Unknown

A Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-396

Type2 Diabetes Mellitus

Korea, Republic of
Sichuan University
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | ALK Fusion Protein Expression | Adjuvant Therapy
Viracta Therapeutics, Inc.

Completed

Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies

Lymphoproliferative Disorders | Epstein-Barr Virus Associated Lymphoma

United States, Brazil
Acerta Pharma BV

Active, not recruiting

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States, Italy, Spain, United Kingdom, Belgium, Denmark, Hungary, Poland, Australia, Germany, Israel, Netherlands, Turkey, France, New Zealand
Weill Medical College of Cornell University
AstraZeneca

Withdrawn

Early Intervention With Acalabrutinib in Patients With High Risk CLL

Chronic Lymphocytic Leukemia | CLL/SLL

United States
Mitsubishi Tanabe Pharma Corporation

Completed

A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia

Chronic Kidney Disease | Hyperphosphatemia | Dialysis

United States, Puerto Rico
Brii Biosciences Limited
TSB Therapeutics (Beijing) CO.LTD

Completed

Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196

COVID-19

China
GE Healthcare
Quintiles, Inc.; Physician Reference Laboratory

Completed

Open Label, Randomized Study of Low Concentration Ioforminol Injections for Use in Abdominal CECT in Healthy Volunteers

Healthy

United States
Guerbet

Terminated

Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography (CINOPSIS CT)

Renal Impairment

United States
Brii Biosciences Limited
TSB Therapeutics (Beijing) CO.LTD

Completed

A Study of Human Monoclonal Antibodies, BRII-196 and BRII-198

COVID-19

China
Brii Biosciences Limited
TSB Therapeutics (Beijing) CO.LTD

Completed

A Phase 1 Study of Human Monoclonal Antibodies, BRII-196 and BRII-198

COVID-19

China
Baker Heart and Diabetes Institute

Completed

Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease

Diabetic Nephropathies

Australia
Mitsubishi Tanabe Pharma Corporation

Terminated

A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Patients With Hyperphosphatemia

Chronic Kidney Disease | Hyperphosphatemia | Dialysis

France, Poland, Spain, Serbia, South Africa, Czech Republic, Germany, Macedonia, The Former Yugoslav Republic of, Italy, United Kingdom
Brii Biosciences, Inc.

Withdrawn

A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19

COVID-19

China
Acerta Pharma BV

Completed

A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196

Hepatic Insufficiency

United States
Mitsubishi Tanabe Pharma Corporation

Completed

Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia

Chronic Kidney Disease | Hyperphosphatemia | Dialysis

United States, Canada
AmtixBio Co., Ltd.
Novotech (Australia) Pty Limited

Completed

A Study of ATB1651 in Adults With Mild to Moderate Onychomycosis

Onychomycosis

New Zealand
Novo Nordisk A/S

Completed

A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools

Diabetes Mellitus, Type 2

Germany
Bracco Diagnostics, Inc

Completed

A Study of Two Iodinated Contrast Agents in Renally Impaired Patients Undergoing Cardiac Angiography

CIN

United States
GE Healthcare

Completed

Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Coronary Angiography

Coronary Artery Disease | Renal Impairment

Sweden
Mitsubishi Tanabe Pharma Corporation

Completed

A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia

Dyslipidemia | Chronic Kidney Disease | Hyperphosphatemia | Dialysis

Poland, Ukraine, Serbia, Russian Federation, Hungary, Malaysia, Italy, Macedonia, The Former Yugoslav Republic of
Bracco Diagnostics, Inc

Completed

Patients With Renal Impairment Undergoing CT

Contrast Induced Nephropathy

United States
Xcovery Holding Company, LLC

Completed

Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer

Advanced Solid Tumors | Non-small Cell Lung Cancer

United States

Search clinical trials for: MGL-3196

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations